Pasithea

We are at the forefront of research into mental health
and brain disorders

Pasithea Therapeutics Corp is a biotech company aiming to solve one of the world’s biggest clinical problems: brain disorders. The long-term aim is to translate research into clinic-ready drugs. 

Our Focus

Our primary focus is on drug development. The aim of our scientific team is to develop new medications that provide better and longer-lasting results for individuals with mental health issues.

1 %

the percentage of the global population suffering from some kind of mental health issue

1 Million

the number of people living with a mental health disorder

Major Depression

is thought to be the second leading cause of disability worldwide

1 Million

the number of people estimated to be suffering from schizophrenia

1 %

the percentage of people globally estimated to be suffering from PTSD by the WHO (World Health Organisation)

1 in 1 People

experienced a mental health problem in the past week

$ 1 Billion

the estimated size of the anxiety and depression treatment market by 2027

$ 1 Trillion

the estimated loss of money to the global economy due to mental disorders (period 2010 – 2030)

Our Clinics

The company’s secondary operations focus on establishing anti-depression clinics across the UK and USA, using our trained pharmacists to administer intravenous infusions of Ketamine.

US Clinics

In the USA, Pasithea has partnered with The I.V. Doc®, a leading operator of mobile clinics, to gain widespread distribution.

UK Clinics

The UK branch of Pasithea’s clinics is operating from a capital light partnership with Zen Healthcare, a leading group of practices with three locations in Marylebone, Holborn and Knightsbridge.

About Us

World Class Management Team

Pasithea is led by Professor Lawrence Steinman and the research is headed up by Dr. Tiago Reis Marques.

Capital Light Infrastructure

Instant operations in London, Los Angeles and New York City.

Diversified Revenue Stream

Antidepressant clinics provide greater visibility of revenue & EBITDA.